Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29470244 | 1.00 | ITK (1.00) | ITKCHEK1 | |
| SCHEMBL5637586 | 0.85 | ITK (0.73) | ITKCHEK1 | |
| SCHEMBL18426827 | 0.85 | ITK (0.73) | ITK | |
| SCHEMBL4121353 | 0.85 | ITK (1.00) | ITK | |
| SCHEMBL144955 | 0.85 | ITK (0.73) | ITKCHEK1 | |
| SCHEMBL4130575 | 0.85 | ITK (0.73) | ITKCHEK1 | |
| SCHEMBL141981 | 0.85 | ITK (1.00) | ITK | |
| SCHEMBL145864 | 0.85 | ITK (1.00) | ITKCHEK1 | |
| SCHEMBL18426830 | 0.85 | ITK (0.73) | ITKCHEK1 | |
| SCHEMBL141689 | 0.85 | ITK (0.73) | ITKCHEK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 69 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110832070-B | Expansion of liquid tumor-derived tumor infiltrating lymphocytes and therapeutic uses thereof | 艾欧凡斯生物治疗公司 | 2024-12-27 | — | — | CN | claimed |
| CN-114478647-A | Organometallic compound, organic light emitting device including the same, and diagnostic composition including the same | 三星电子株式会社 | 2022-05-13 | — | — | CN | claimed |
| CN-113861200-A | Imidazo [4,5-b ] pyrazine compound, preparation method and application thereof | 上海医药集团股份有限公司 | 2021-12-31 | — | — | CN | claimed |
| CN-110938048-A | High-efficiency synthesis of dihydrofuran derivative by Lewis acid catalyzed insertion reaction | 四川大学 | 2020-03-31 | — | — | CN | claimed |
| US-7101884-B2 | Tyrosine kinase inhibitors | MERCK & CO., INC. (US) | 2006-09-05 | — | — | US | claimed |
| EP-1633738-A2 | NOVEL INDOLE DERIVATIVES, METHOD OF PREPARING SAME IN THE FORM OF MEDICAMENTS, PHARMACEUTICAL COMPOSITIONS AND, IN PARTICULAR, KDR INHIBITORS | Aventis Pharma S.A. (FR) | 2006-03-15 | — | — | EP | claimed |
| US-20050070546-A1 | Tyrosine kinase inhibitors | MERCK SHARP & DOHME CORP. | 2005-03-31 | — | — | US | claimed |
| US-20040242559-A1 | Novel indole derivatives, preparation thereof as medicinal products and pharmaceutical compositions, and especially as KDR inhibitors | AVENTIS PHARMA S.A. (FR) | 2004-12-02 | — | — | US | claimed |
| WO-2004096792-A2 | NOVEL INDOLE DERIVATIVES, METHOD OF PREPARING SAME IN THE FORM OF MEDICAMENTS, PHARMACEUTICAL COMPOSITIONS AND, IN PARTICULAR, KDR INHIBITORS | AVENTIS PHARMA S.A. (FR) | 2004-11-11 | — | — | WO | claimed |
| US-20260144870-A1 | PROCESSES FOR PRODUCTION OF TUMOR INFILTRATING LYMPHOCYTES AND USES OF SAME IN IMMUNOTHERAPY | IOVANCE BIOTHERAPEUTICS, INC. (US) | 2026-05-28 | — | — | US | disclosed |
| US-20260124242-A1 | EXPANSION OF TUMOR INFILTRATING LYMPHOCYTES FROM LIQUID TUMORS AND THERAPEUTIC USES THEREOF | IOVANCE BIOTHERAPEUTICS INC (US) | 2026-05-07 | — | — | US | disclosed |
| US-12473532-B2 | Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy | IOVANCE BIOTHERAPEUTICS, INC. (US) | 2025-11-18 | — | — | US | disclosed |
| CN-110832070-B | Expansion of liquid tumor-derived tumor infiltrating lymphocytes and therapeutic uses thereof | 艾欧凡斯生物治疗公司 | 2024-12-27 | — | — | CN | disclosed |
| US-20240392245-A1 | EXPANSION OF TUMOR INFILTRATING LYMPHOCYTES FROM LIQUID TUMORS AND THERAPEUTIC USES THEREOF | IOVANCE BIOTHERAPEUTICS INC (US) | 2024-11-28 | — | — | US | disclosed |
| US-20050070546-A1 | Tyrosine kinase inhibitors | MERCK SHARP & DOHME CORP. | 2005-03-31 | — | — | US | disclosed |
| US-20050032869-A1 | Pyrazolyl-indole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them | PHARMACIA ITALIA S.P.A. (IT) | 2005-02-10 | — | — | US | disclosed |
| WO-2005005414-A2 | PYRAZOLYL-INDOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM | PHARMACIA ITALIA S.P.A. (IT) | 2005-01-20 | — | — | WO | disclosed |
| US-20040242559-A1 | Novel indole derivatives, preparation thereof as medicinal products and pharmaceutical compositions, and especially as KDR inhibitors | AVENTIS PHARMA S.A. (FR) | 2004-12-02 | — | — | US | disclosed |
| WO-2004096792-A2 | NOVEL INDOLE DERIVATIVES, METHOD OF PREPARING SAME IN THE FORM OF MEDICAMENTS, PHARMACEUTICAL COMPOSITIONS AND, IN PARTICULAR, KDR INHIBITORS | AVENTIS PHARMA S.A. (FR) | 2004-11-11 | — | — | WO | disclosed |
| WO-2003024969-A1 | TYROSINE KINASE INHIBITORS | MERCK & CO., INC. (US) | 2003-03-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050032869-A1 | Pyrazolyl-indole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them | MAP3K9, MAP3K20, MAP3K19 | ITK 392/4885CHEK1 242/4885 |
| US-20260124242-A1 | EXPANSION OF TUMOR INFILTRATING LYMPHOCYTES FROM LIQUID TUMORS AND THERAPEUTIC USES THEREOF | PBK, LTK, BLK | ITK 4/4885CHEK1 597/4885 |
| US-20040242559-A1 | Novel indole derivatives, preparation thereof as medicinal products and pharmaceutical compositions, and especially as KDR inhibitors | FLT4, KDR, CYP3A4 | ITK 1186/4885CHEK1 1476/4885 |
| US-20260144870-A1 | PROCESSES FOR PRODUCTION OF TUMOR INFILTRATING LYMPHOCYTES AND USES OF SAME IN IMMUNOTHERAPY | PBK, ITK, IL2 | ITK 2/4885CHEK1 390/4885 |
| US-20050070546-A1 | Tyrosine kinase inhibitors | ERBB2, TYRO3, TIE1 | ITK 377/4885CHEK1 499/4885 |
| US-20240392245-A1 | EXPANSION OF TUMOR INFILTRATING LYMPHOCYTES FROM LIQUID TUMORS AND THERAPEUTIC USES THEREOF | PBK, MALT1, BCL9L | ITK 264/4885CHEK1 2758/4885 |
| US-12473532-B2 | Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy | ICOS, PBK, IL2 | ITK 83/4885CHEK1 3710/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.